CEDx Labs Moves to Larger Space to Support Growing Diagnostic Menu Including COVID-19 Serology Testing

May, 24 2020

Nashua/Boston, May 1, 2020 — CEDx Labs Inc., Comprehensive Esoteric Diagnostic Labs – established in 2018 to validate assays and conduct clinical, preclinical, and veterinary diagnostic sample testing, has announced they have moved into a new larger facility in Nashua Technology Park, New Hampshire.

This facility is three times the size of their previous space and provides the company the room to expand its Clinical and Veterinary Diagnostics portfolio, as well as supporting the research client’s needs, it also affords the capability for CEDx to grow and add new technologies, while continuing to provide the personalized professional experience the clients expect.

This location provides easy proximity to the Boston Biotech Super Cluster, providing accessibility within the normal commuting range for Massachusetts based Pharma and Biotech organizations, without the heaviest of traffic congestion.

In this new facility, CEDx Labs has already initiated validation of LDT level COVID-19 IgG and IgM antibody assays. CEDx recognizes COVID-19-specific serology testing as a major ongoing public health need and that many organizations will employ this testing as an essential tool to ensure health and safety of their employees.

Eric Wexler, CEDx VP of Business Development comments “We are excited to move into this next phase where we can provide support that is crucially needed in underserved populations and to enable the efforts of our partners to supply effective treatment. As we see new and evolving health risks and novel diseases, we continue to execute as a nimble organization that can pivot to address urgent needs.”

About CEDx Labs Inc.
CEDx Labs provides bioanalysis, as a diagnostic lab and consulting service focusing on rare and emerging disorders and disease. Its experts provide comprehensive insight and analysis with in house developed assays as well as supporting NYS submissions for other clinical labs. Currently focusing on providing discovery level analyses as well as full CLIA validation of ELISA and IFA assays supporting diagnostic and drug development. The company is wholly owned by executives with established and proven history of supporting pharma/biotech efforts, clinical, and veterinary diagnostic clients.

At CEDx Labs: Related Links
Eric J. Wexler, MBA https//www.cedxlabs.com
VP of Business Development

Download PDF

Back to News